

Oclacitinib

- Drug Information

Brand Names:

Apoquel®

Pharmacology:

Synthetic Janus Kinase (JAK) inhibitor. Oclacitinib inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.

Oclacitinib is not a corticosteroid or an antihistamine.

Indications:

For the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Contraindications:

- General

Apoquel® is not for use in dogs less than 12 months of age.

Apoquel® is not for use in dogs with serious infections.

Apoquel® may increase susceptibility to infection, including demodicosis, and exacerbate neoplastic conditions

Not for use in breeding dogs, or pregnant or lactating bitches.

The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.

Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis and neoplasia.

Interactions:

- Category Interactions

- Glucocorticoid

Safety has not been evaluated in combination with glucocorticoids.

- Immunosuppressive drug

Safety has not been evaluated in combination with systemic immunosuppressants.

- Drug Interactions

- CycloSPORINE

Safety has not been evaluated in combination with CycloSPORINE.

Adverse Effects:

- General

Adverse reactions reported included diarrhea, vomiting, anorexia, polydipsia, new cutaneous or subcutaneous lump, and lethargy. Decreased leukocytes (neutrophil, eosinophil, and monocyte counts) and serum globulin, and increased cholesterol and lipase are also possible.

Darkening areas of skin and fur is also possible.

Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

Dosages:

- Small Animal

- Dog

0.4 - 0.6 mg / kg body weight, administered orally twice daily for up to 14 days, and then once daily for maintenance therapy.

May be administered with or without food.

Special Notes:

None